Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Spero Therapeutics and Innovent Biologics have entered an exclusive licensing agreement for SP001 (IBI355), a Phase 2-ready anti-CD40L antibody candidate. Under the deal structure, Spero gains global rights excluding Greater China, while Innovent retains development rights in its home market. The upfront payment combined with potential milestone payments totaling ~$1.1 billion suggests confidence in the asset's clinical and commercial potential across two distinct indications.

The dual-track development strategy targets high-unmet-need populations: Spero will pursue IgG4-related disease (IgG4-RD) in developed markets beginning Q2 2027, while Innovent simultaneously advances Sjögren's disease (SjD) in China by early 2027. Both conditions are chronic, autoimmune-driven with limited therapeutic options, positioning SP001 as potentially differentiated within the anti-CD40L space. The tiered royalty structure creates aligned incentives for both parties post-approval.

This transaction reflects continued sector appetite for selective immunology assets, particularly those addressing fibroinflammatory conditions. The staggered global approach may reduce development risk by diversifying regulatory and market exposure. However, Phase 2-stage risk remains material; clinical efficacy and safety data will be critical gates for value realization.

Sector implication: The deal signals ongoing biotech M&A activity and capital deployment toward precision immunology. For Health Care investors, this represents a mid-stage validation event typical of thriving biotech licensing markets, though individual stock impact depends on company-specific execution risk and pipeline diversity.